Biondi-ZoccaiG. Why interventional cardiologists may be the most suitable specialists for the endovascular management of peripheral artery disease. Minerva Cardioangiol. 2013;61:367–370.
2.
ShanmugasundaramMRamVKLuftUCet al. Peripheral arterial disease–what do we need to know?Clin Cardiol. 2011;34:478–482.
3.
TASC Steering Committee, JaffMRWhiteCJet al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Endovasc Ther. 2015;22:663–677.
4.
KleinAJJaffMRGrayBHet al. SCAI appropriate use criteria for peripheral arterial interventions: an update. Catheter Cardiovasc Interv. 2017;90:E90–E110.
5.
Biondi-ZoccaiGSangiorgiGD’AscenzoFet al. Drug-eluting balloons for peripheral artery disease: a meta-analysis of 7 randomized clinical trials and 643 patients. Int J Cardiol. 2013;168:570–571.
6.
LairdJRSchneiderPATepeGet al; IN.PACT SFA Trial Investigators. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66:2329–2338.
7.
RosenfieldKJaffMRWhiteCJet al; LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–153.
8.
TepeGSchnorrBAlbrechtTet al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8:102–108.
9.
MicariAVadalàGCastriotaFet al. 1-Year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-Long study. JACC Cardiovasc Interv. 2016;9:950–956.
10.
CejnaMThurnherSIlliaschHet al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol. 2001;12:23–31.
11.
GrayBHSullivanTMChildsMBet al. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. J Invasive Cardiol. 2004;16 (suppl A):3A–9A.
12.
MarmagkiolisKHakeemAChoksiNet al. 12-Month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: beyond balloon angioplasty. Catheter Cardiovasc Interv. 2014;84:555–564.
13.
DudaSHBosiersMLammerJet al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701–710.
14.
LammerJBosiersMZellerTet al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011;54:394–401.
15.
DakeMDAnselGMJaffMRet al; Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495–504.
16.
DakeMDAnselGMJaffMRet al. Zilver PTX Investiga-tors. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–1483.
17.
SiablisDKitrouPMSpiliopoulosSet al. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. JACC Cardiovasc Interv. 2014;7:1048–1056.
18.
LammerJZellerTHauseggerKAet al. Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial. Cardiovasc Intervent Radiol. 2015;38:25–32.
19.
GeraghtyPJMewissenMWJaffMRet al; VIBRANT Investigators. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg. 2013;58:386–95.e4.
20.
LammerJBosiersMDelooseKet al. Bioresorbable everolimus-eluting vascular scaffold for patients with peripheral artery disease (ESPRIT I): 2-year clinical and imaging results. JACC Cardiovasc Interv. 2016;9:1178–1187.
21.
GiordanoAFerraroPCorcioneNet al. Endovascular therapy for infrainguinal artery disease with coronary devices: a retrospective observational study comparing drug-eluting stents versus bioresorbable vascular scaffolds. Angiology. 2017;68:59–66.
22.
PhillipsJAFallsAKolluriRet al. Full drug-eluting stent jacket: 2-year results of a single-center experience with Zilver PTX stenting for long lesions in the femoropopliteal arteries. J Endovasc Ther. 2018;25:295–301.
